IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation to IB4000 for the treatment of
IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation to IB4000 for the treatment of